How one start­up fore­told the neu­ro­science re­nais­sance af­ter '50 years of shit­show'

In the past cou­ple of years, some­thing cu­ri­ous has hap­pened: Phar­ma and VC dol­lars start­ed gush­ing in­to neu­ro­science re­search.

Bio­gen’s con­tro­ver­sial new Alzheimer’s drug Aduhelm has been ap­proved on the ba­sis of re­mov­ing amy­loid plaque from the brain, but the new neu­ro-fo­cused phar­ma and biotechs have much lofti­er aims. Sig­nif­i­cant­ly curb­ing or even cur­ing the most no­to­ri­ous dis­or­ders would prove the Holy Grail for a com­plex sys­tem that has tied the world’s best drug de­vel­op­ers in knots for decades.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.